/PRNewswire/ Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and commercialize KHK4083, which is.
Share this article
Share this article
BEDMINSTER, N.J., May 4, 2021 /PRNewswire/ Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, recently named Ernesto Aycardi, M.D., to the position of Chief Development Officer on April 26, and is welcoming Eslie Dennis, M.D., MBChB, FCP(SA) in the role of Chief Medical Officer today. These appointments come at a pivotal time for the company, as the North America region aims to realize the full potential of its existing commercial portfolio and compounds being investigated in the pipeline. In particular, the company is working on plans to advance KW-6356, a selective antagonist of adenosine A2A receptors, and KHK4083, an Anti-OX40 Fully Human Antibody, and is also collaborating with partner MEI Pharma to complete the pivotal study and shape a broader development program for zandelisib, a selective PI3Kδ inhibitor.
Kyowa Kirin North America, the Bedminster-based unit of Japan’s Kyowa Kirin Co. Ltd., said this week that it is continuing its business integration initiative, merging a pair of units to streamline its structure.
The pharmaceutical company said in a news release that it is merging its Kyowa Kirin Research and Kyowa Kirin Development companies into one business, called Kyowa Kirin Inc., as part of its ongoing North American Business Integration, or NABI, initiative.
The goal of the initiative is a simpler business structure and common set of processes and systems.
“The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these (pipeline) opportunities,” Gary Zieziula, president of KKNA, said in a prepared statement. “Through NABI, we’re working to enable more efficient collaborations and business support for the functions that discover, develop and deliver first-in-class medicines that can have a profound impact o
Press release content from Business Wire. The AP news staff was not involved in its creation.
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
February 18, 2021 GMT
TOKYO (BUSINESS WIRE) Feb 18, 2021
For Medical Media only. Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.
KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT ® defucosylation technology to enhance its antibody dependent cellular cytotox